Senseonics develops and provides the Eversense Continuous Glucose Monitoring (CGM) System, which is a long-term implantable device designed for diabetes management.

Senseonics

Senseonics, Incorporated | 11,715 followers on LinkedIn. Creators of the first and only long-term implantable CGM | Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.   Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring (&quot;CGM&quot;​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.  

The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Technical Executive - Engineering R&D - IoT and AI - Technology Development - Product Management - Program Management - Seeking VP, Director and Sr…

Brian Thomas

Board Member and Audit Committee Chair

Doug Prince

Leading digital innovation at the heart of science and technology

Everett Lee

Medical Device Regulatory Affairs Professional, R&D Scientist, Project and Personnel Manager

Mark Mortellaro, PhD, RAC-Devices, RCC-MDR

Senseonics, Incorporated

We are delighted to announce our new agreement with Ascensia Diabetes Care “We are extremely excited to be partnering with Ascensia, a leader in the global diabetes space. Ascensia is well known for their high-quality CONTOUR products used by more than 10 million patients world-wide to help manage their diabetes. We believe their global commercial infrastructure and commitment to the Eversense systems will drive market adoption while allowing Senseonics to focus on further development of our implanted technology.” – Tim Goodnow

Eversense NOW

Eversense CGM

Eversense NOW US

Senseonics Guide

Eversense

Domain Not Resolving

DNSSEC

Microsoft

AWS Global Accelerator

Zoom

Zoom Video Conferencing

Cogent Communications

Proofpoint URL Defense

Investis

TalkPoint

Doug Roeder

Ed Fiorentino

Arthur Colvin

Senior Research Fellow

M. James Barrett

Founder

Katherine S. Tweden

Vice President, Clinical Sciences

Mukul Jain

Chief Operating Officer

Mirasol Panlilio

VP, Global Sales and Marketing

Abhi Chavan

Vice President, Engineering, R&D

Francine R. Kaufman

Chief Medical Officer

Stephen DeFalco

Chairman

Southern US Companies With Less Than $500M in Revenue (Top 10K)

Southern US Companies With More Than 50 Employees (Top 10K)

East Coast Companies With More Than 10 Employees (Top 10K)

Biotechnology Public Companies With More Than 50 Employees

Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.

Post-IPO Equity - Senseonics

Hercules Capital

Post-IPO Debt - Senseonics

PHC Holdings

Masters Capital Management

New Enterprise Associates

Roche Finance

Venture Round - Senseonics

Computer and Software Products and Electrical and Scientific Products

Germantown

Maryland

United States

North America

Senseonics stock dips on $16M securities offering (NYSE:SENS)

FDA clears Senseonic’s Eversense one-year implantable CGM

Senseonics expects a Q4 launch for 365-day CGM, offers full-year outlook

Senseonics FY24 Revenue View Falls Short of Estimates

Senseonics sees FY24 revenue $22M-$24M, consensus $26.01M

Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook

Senseonics, Rimidi partner on remote diabetes monitoring program

Senseonics Releases Q1 Results; Submits 365-Day ICGM To FDA

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

A continuous glucose monitoring system designed for long-term use, involving an under-the-skin sensor, a smart transmitter, and a mobile app for real-time glucose level management.

An extended version of the Eversense CGM, offering glucose monitoring and management for up to 180 days with an implantable sensor, smart transmitter, and app.

A support program to assist patients in qualifying for the Eversense CGM system, including insurance appeals and product usage education.

A financial assistance program designed to help reduce out-of-pocket costs for patients whose insurance does not cover the Eversense E3 CGM system.

India

Asia

Malaysia

Turkey

Europe

HTML5

Amazon EC2

Google Analytics

.NET 4.5

Microsoft Outlook

Wordpress

GoDaddy

Office 365

Google Tag Manager

Google Fonts

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

news impact assignment basic	general
public peers	general	Nov 14, 2024 7:11 AM	4f87e926
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 14, 2024 7:11 AM	fc1986a2
crunchbase trigger	general	Nov 14, 2024 7:11 AM	d18e2bfb
crunchbase profile	general	Nov 15, 2024 1:40 AM	2733d6c9
li profile	general	Nov 14, 2024 7:11 AM	834e8e4b
translate crunchbase fundingrounds	general	Nov 15, 2024 2:37 AM	b6615899
peers	general	Nov 14, 2024 7:11 AM	d57a6734
news basic	general	Nov 14, 2024 7:11 AM	2d58bd56
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SENSEONICS

Senseonics

Last Close

0.32

21/11 21:00

Market Cap

237.15M

Beta: -

Volume Today

4.47M

Avg: -